Effect of loratadine on the dissolution and bioavailability of gliclazide from its hydroxypropyl-β-cyclodextrin complex
- 230 Downloads
Gliclazide (GZD) is a hypoglycemic agent that has slow dissolution rate and variable bioavailability. Inclusion complex of GZD with hydroxypropyl-β-cyclodextrin (HPβCD) was prepared with the molar ratio 1:2 by solvent evaporation method. The complex was characterized using Fourier transform infra-red spectroscopy and differential scanning calorimetry. Solubility and in vitro dissolution studies were performed at acidic and neutral pH values. Furthermore, the competitive interactions of the antihistamine loratadine (LOR) on the binding of GZD to HPβCD were studied by performing solubility and in vitro dissolution studies of GZD-HPβCD complex in presence and absence of the competing drug at pH values 4.5 and 6.8. GZD-HPβCD complex was found to enhance the dissolution of the drug in all pH values studied. The presence of LOR with GZD-HPβCD complex led to some pH dependent changes in the dissolution of the complex which supported the results obtained from the solubility studies. Using blood glucose level as a pharmacodynamic marker that reflects the bioavailability of GZD, in vivo studies have shown that GZD when given as its HPβCD complex together with LOR exhibits about 25 % lower bioavailability (effect) compared to GZD alone. In an attempt to explain the in vivo and dissolution studies, higher order complexes (aggregates) involving LOR, GZD and HPβCD were proposed. The formation of such larger complexes was supported by stoichiometric and diffusion studies.
KeywordsHydroxypropyl-β-cyclodextrin Gliclazide Loratadine Dissolution Displacement
The authors would like to thank the Deanship of Academic Research at The University of Jordan for continuing financial support. The authors are also grateful to the Applied Sciences University for the financial support granted to this research project (Grant No. DRGS-2011-2).
Compliance with ethical standards
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.He, Z.G., Li, Y.S., Zhang, T.H., Tang, X., Zhao, C., Zhang, R.H.: Effects of 2-hydroxypropyl-beta-cyclodextrin on pharmacokinetics of digoxin in rabbits and humans. Pharmazie 59, 200–202 (2004)Google Scholar
- 7.Muraoka, A., Tokumura, T., Machida, Y.: In-vitro evaluation of cinnarizine as a competing agent to beta-cyclodextrin inclusion complexes: effect of cinnarizine on the membrane permeation rate of progesterone from its beta-cyclodextrin inclusion complex. Yakugaku Zasshi 128, 89–95 (2008)CrossRefGoogle Scholar
- 15.Lo, Y.-K., Hsu, C.-P., Tsai, T.-G., Cham, T.-G.: Comparison of the solubility and dissolution rate of gliclazide-β-cyclodextrin inclusion complexes prepared by liquid/liquid extraction and neutralization. J. Food Drug Anal. 14, 230–235 (2006)Google Scholar
- 18.Sharma, G.S., Srikanth, M.V., Sunil, S.A., Sreenivasa Rao, N., Ramana Murthy, K.V.: Dissolution rate enhancement of poorly soluble gliclazide by complexation with hydroxy propyl β cyclodextrin. Res. J. Pharm. Biol. Chem. Sci. 2, 814–823 (2011)Google Scholar
- 20.Khan, M.Z., Rausl, D., Zanoski, R., Zidar, S., Mikulcić, J.H., Krizmanić, L., Eskinja, M., Mildner, B., Knezević, Z.: Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro–in vivo correlation. Biol. Pharm. Bull. 27, 1630–1635 (2004)CrossRefGoogle Scholar
- 23.Higuchi, T.A., Connors, K.A.: Phase-solubility techniques. Adv. Anal. Chem. Instr. 4, 117–122 (1965)Google Scholar
- 24.Etuk, E.U.: Animals models for studying diabetes mellitus. Agric. Biol. J. N. Am. 1, 130–134 (2010)Google Scholar
- 25.Varma, M.M., Kumar, P.S.: Formulation and evaluation of gliclazide tablets containing PVP-K30 and Hydroxy propyl-β-cyclodextrin solid dispersion. Inter. J. Pharm. Sci. Nano. 5, 1706–1719 (2012)Google Scholar
- 32.Demirturk, E., Öner, L.: Solubility and dissolution properties of gliclazide. FABAD J. Pharm. Sci. 29, 21–25 (2004)Google Scholar
- 33.Lakka, N.S., Goswami, N.: Solubility and dissolution profile studies of gliclazide in pharmaceutical formulations by RP-HPLC. Int. Res. J. Pharm. 3, 126–129 (2012)Google Scholar
- 36.Aggarwal, S., Singh, P.N., Mishra, B.: Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes. Pharmazie 57, 191–193 (2002)Google Scholar
- 39.Al-Salami, H., Butt, G., Tucker, I., Mikov, M.: Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol. Rep. 60, 532–541 (2008)Google Scholar